CYFRA21-1 might be predictive marker in advanced NSCLC

March 15, 2012, International Association for the Study of Lung Cancer

Researchers found that CYFRA and change in levels of CYFRA were found to be reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen.

As part of a study performed by the Cancer and Leukemia Group B in advanced lung cancer, serum CYFRA levels were measured at baseline and after the first cycle of treatment. According to the study, "higher baseline CYFRA concentrations portend worse overall and failure free survival. Additionally, this trial confirmed the significance of the cut point of a 27 percent reduction in log CYFRA after chemotherapy is of value in determining benefit from treatment."

Researchers warn that further studies are needed, but "if confirmed, this would provide a simple and inexpensive approach to assessment of response to treatment."

The lead author of this work is IALSC member Dr. Martin Edelman. IASLC member co-authors include Dr. Everett Vokes and Dr. Robert Kratzke.

Explore further: Panel of serum biomarkers may reduce number of lung biopsies needed

Related Stories

Panel of serum biomarkers may reduce number of lung biopsies needed

March 15, 2012
A panel of serum biomarkers could help predict the level of lung cancer risk in high-risk patients, offering doctors an option before proceeding with a biopsy. Research presented in the April 2012 issue of the International ...

High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy

July 5, 2011
High epidermal growth factor receptor (EGFR) expression was a good predictor of which lung cancer patients would survive longer when cetuximab (Erbitux) was added to first-line chemotherapy, according to research presented ...

EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy

July 5, 2011
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the ...

Pleurectomy/decortication proposed preferred surgical procedure

March 15, 2012
Patients with early stage malignant pleural mesothelioma (MPM), a cancer that develops in the lining of the lungs, may be eligible for aggressive multi-modality therapy involving surgery, radiotherapy and chemotherapy. There ...

Recommended for you

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.